Glucose-Insulin-Potassium Infusion May Cause Early Harm After STEMI

New analyses reveal a mortality risk in the first 3 days and confirm a lack of longer-term benefit.

Although several small clinical trials have suggested the utility of glucose-insulin-potassium (GIK) infusion following ST-segment-elevation MI (STEMI), in the largest assessment to date, the CREATE-ECLA study (Journal Watch Cardiology Mar 18 2005), GIK infusion had a neutral effect on 30-day mortality. In an industry-funded follow-up trial, investigators for the Organization for the Assessment of Strategies for Ischemic Syndromes-6 (OASIS-6) evaluated the effect of GIK infusion versus no infusion on 30-day and 6-month mortality and heart failure in 2748 patients with STEMI. They performed prespecified analyses of the combined trial data on 22,943 patients enrolled in the OASIS-6 and CREATE-ECLA studies.

Subjects randomized to intervention w…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

Glucose-Insulin-Potassium Infusion May Cause Early Harm After STEMI

Topics

Reviewing Author